536 related articles for article (PubMed ID: 27494802)
21. Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4.
Wakchaure P; Velayutham R; Roy KK
J Biomol Struct Dyn; 2019 Aug; 37(12):3048-3057. PubMed ID: 30079805
[TBL] [Abstract][Full Text] [Related]
22. Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.
Liu Z; Li Y; Chen H; Lai HT; Wang P; Wu SY; Wold EA; Leonard PG; Joseph S; Hu H; Chiang CM; Brasier AR; Tian B; Zhou J
J Med Chem; 2022 Feb; 65(3):2388-2408. PubMed ID: 34982556
[TBL] [Abstract][Full Text] [Related]
23. 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1).
Hügle M; Lucas X; Weitzel G; Ostrovskyi D; Breit B; Gerhardt S; Einsle O; Günther S; Wohlwend D
J Med Chem; 2016 Feb; 59(4):1518-30. PubMed ID: 26731611
[TBL] [Abstract][Full Text] [Related]
24. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
25. Identification of potent BRD4-BD1 inhibitors using classical and steered molecular dynamics based free energy analysis.
Gupta A; Purohit R
J Cell Biochem; 2024 Mar; 125(3):e30532. PubMed ID: 38317535
[TBL] [Abstract][Full Text] [Related]
26. Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning.
Wang J; Yang W; Zhao L; Wei B; Chen J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675678
[TBL] [Abstract][Full Text] [Related]
27. Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain.
Lolli G; Battistutta R
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2161-4. PubMed ID: 24100334
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4.
Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C
Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120
[TBL] [Abstract][Full Text] [Related]
29. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.
Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y
Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation.
Barman S; Sahoo SS; Padhan J; Sudhamalla B
J Biomol Struct Dyn; 2023 Dec; 41(20):10569-10581. PubMed ID: 36524430
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
[TBL] [Abstract][Full Text] [Related]
32. Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain.
Heinzelmann G; Henriksen NM; Gilson MK
J Chem Theory Comput; 2017 Jul; 13(7):3260-3275. PubMed ID: 28564537
[TBL] [Abstract][Full Text] [Related]
33. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
35. Binding Kinetics versus Affinities in BRD4 Inhibition.
Kuang M; Zhou J; Wang L; Liu Z; Guo J; Wu R
J Chem Inf Model; 2015 Sep; 55(9):1926-35. PubMed ID: 26263125
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
37. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
[TBL] [Abstract][Full Text] [Related]
38. In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity.
Deepak V; Wang B; Koot D; Kasonga A; Stander XX; Coetzee M; Stander A
Chem Biol Drug Des; 2017 Jul; 90(1):97-111. PubMed ID: 28032455
[TBL] [Abstract][Full Text] [Related]
39. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
[TBL] [Abstract][Full Text] [Related]
40. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.
Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
Chem Biol Drug Des; 2018 Mar; 91(3):828-840. PubMed ID: 29139214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
